-

Endologix to Present in Two Upcoming Healthcare Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the company will be presenting in two upcoming healthcare conferences:

  • The 2023 Stifel Healthcare Conference
    Wednesday, November 15, 2023, at 10:55 AM Eastern Time.

  • Canaccord Genuity Medical Technology and Diagnostics Forum
    Thursday, November 16, 2023, at 9:30 AM Eastern Time.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

Industry:

Endologix LLC

Release Versions
English

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

More News From Endologix LLC

Endologix Announces that Scott Huennekens Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that R. Scott Huennekens has been appointed to the Endologix Board of Directors. Mr. Huennekens is a highly regarded medtech CEO, chairperson, entrepreneur and investor, serving an impressive list of companies. Previously, he led Volcano Corp. (VOLC), a leader in minimally invasive...

Endologix Announces 1000 patients treated with the DETOUR™ System

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that 1,000 patients have now been treated with Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR System. This milestone includes patients in the DETOUR1 and DETOUR2 clinical studies as well as those treated post-commercial launch (July 2023). PTAB with the DETOUR System offe...

Endologix Appoints Andrew Davis as Chief Commercial Officer

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, is pleased to announce the appointment of Andrew Davis as its new Chief Commercial Officer, effective immediately. Andrew joins Endologix with an extensive background in commercial leadership, having most recently served as the Chief Commercial Officer at Silk Road Medical where he successfully spearheaded the go-to-market strategy for a groun...
Back to Newsroom